window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Parkinson’s disease

  • Biotech & Pharma Business,Clinical & Regulatory,Research & Development

    Mission Therapeutics signs US$292M deal for acute kidney injury programme

    Mission Therapeutics has signed a deal worth up to US$292 [...]

    July 20, 2026
  • Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Research & Development

    Remepy study links Hybridopa brain changes to improved Parkinson’s outcomes

    Remepy has published new peer-reviewed findings showing that its investigational [...]

    July 2, 2026
  • Pharmaceuticals and therapeutics,Therapeutic Areas

    Scenic Biotech joins Michael J. Fox Foundation Parkinson’s research programme

    Scenic Biotech has joined the Michael J. Fox Foundation’s LRRK2 [...]

    June 11, 2026
  • Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    Deep Science Ventures and Medicines Discovery Catapult target blood-brain barrier challenge

    Deep Science Ventures and Medicines Discovery Catapult have launched a [...]

    June 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764

    AC Immune has initiated a Phase 1 trial of its [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AC Immune interim Phase 2 data suggest ACI-7104.056 may slow Parkinson’s disease progression

      AC Immune SA has reported positive interim results from [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Modulight Biotherapeutics raises $12 million seed funding for optogenetic therapy development

    Modulight Biotherapeutics has raised $12.2 million in a Seed funding [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Celon Pharma receives FDA clearance for Phase 3 trial of CPL’36 in schizophrenia

    Celon Pharma S.A. has received FDA clearance to advance its [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    NRG Therapeutics closes oversubscribed £50m series B to advance clinical data in Parkinson’s and proof of concept in ALS/MND

    NRG Therapeutics Ltd, a neuroscience company developing treatments targeting mitochondrial [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
  • Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial
    Categories: Clinical & Regulatory, Medical devices, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top